The Journal of Thoracic and Cardiovascular Surgery
Volume 117, Issue 4 , Pages 744-750 , April 1999

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer

Received 17 June 1998 ,Revised 21 September 1998 ,Accepted 19 October 1998.

  • Image Result

    Kaplan-Meier estimation of survival in patients with and without TP53 mutations. A significant survival advantage was found for patients with normal TP53 genotype. Patients with normal TP53 genotype w

    Kaplan-Meier estimation of survival in patients with and without TP53 mutations. A significant survival advantage was found for patients with normal TP53 genotype. Patients with normal TP53 genotype were found to correspond to those with treatment response.

  • Image Result
    Sequencing analysis showing part of exon 7 of the TP53 gene from normal and tumor DNA of patient 855 (with NSCLC unresponsive to cisplatin-based therapy). Tumor sequence shows mutation in codon 248, a

    Sequencing analysis showing part of exon 7 of the TP53 gene from normal and tumor DNA of patient 855 (with NSCLC unresponsive to cisplatin-based therapy). Tumor sequence shows mutation in codon 248, a cytosine to thymine transition (arrow).

☆ Supported by the Österreichische Nationalbank, project number 7003.

☆☆ Address for reprints: Daniela Kandioler-Eckersberger, MD, Department of Surgery, University of Vienna-Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

★ 12/1/95291

PII: S0022-5223(99)70295-3

The Journal of Thoracic and Cardiovascular Surgery
Volume 117, Issue 4 , Pages 744-750 , April 1999

Article Tools

* Image Usage & Resolution